News Releases | Insmed Incorporated

Month Year

Email Alerts

Jun 23, 2026

Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory

Read more
Jun 4, 2026

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
May 27, 2026

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

Read more
May 7, 2026

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

Read more
May 6, 2026

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
- Photos 2
- Video 3
Read more
May 4, 2026

Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026

Read more
Apr 30, 2026

Insmed to Present at May 2026 Investor Conferences

Read more
Apr 23, 2026

Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026

Read more
Apr 7, 2026

Insmed Provides Clinical Update on Phase 2b CEDAR Study

Read more
Mar 23, 2026

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

Read more
Mar 5, 2026

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Feb 19, 2026

Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

Read more
Feb 13, 2026

Insmed To Present at March 2026 Investor Conferences

Read more
Feb 5, 2026

Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026

Read more
Jan 28, 2026

Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress

Read more
Jan 9, 2026

Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Read more
Jan 2, 2026

Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference

Read more
Dec 17, 2025

Insmed Provides Clinical and Business Update

Read more
Dec 4, 2025

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Nov 18, 2025

European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

Read more
Nov 13, 2025

Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good

Read more
Nov 5, 2025

Insmed To Present at November and December 2025 Investor Conferences

Read more
Oct 30, 2025

Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update

Read more
Oct 23, 2025

Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List

Read more
Oct 17, 2025

CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

Read more
Oct 16, 2025

Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025

Read more
Oct 15, 2025

Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025

Read more
Sep 22, 2025

Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025

Read more
Sep 5, 2025

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Aug 21, 2025

Insmed To Present at September Investor Conferences

Read more
Aug 12, 2025

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Read more
Aug 7, 2025

Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update

Read more
Jul 24, 2025

Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025

Read more
Jun 11, 2025

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

Read more
Jun 11, 2025

Insmed Announces Proposed $650 Million Public Offering of Common Stock

Read more
Jun 10, 2025

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

Read more
Jun 4, 2025

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
May 28, 2025

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

Read more
May 21, 2025

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

Read more
May 8, 2025

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

Read more
Apr 29, 2025

Insmed To Present at the BofA Securities 2025 Health Care Conference

Read more
Apr 24, 2025

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

Read more
Apr 23, 2025

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

Read more
Apr 23, 2025

Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

Read more
Mar 25, 2025

Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

Read more
Mar 10, 2025

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Feb 24, 2025

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

Read more
Feb 20, 2025

Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

Read more
Feb 11, 2025

Insmed To Present at March 2025 Investor Conferences

Read more
Feb 10, 2025

Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025

Read more
Feb 7, 2025

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Feb 6, 2025

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

Read more
Jan 10, 2025

Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference

Read more
Jan 3, 2025

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Jan 2, 2025

Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Read more
Dec 6, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Dec 2, 2024

Insmed To Present at December 2024 Investor Conferences

Read more
Nov 7, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Nov 6, 2024

Insmed To Present at November 2024 Investor Conferences

Read more
Oct 31, 2024

Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update

Read more
Oct 24, 2024

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

Read more
Oct 23, 2024

Insmed Unites Across Communities Around the World During Third Annual Global Day of Good

Read more
Oct 17, 2024

Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024

Read more
Oct 8, 2024

New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results

Read more
Oct 4, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Sep 6, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Aug 8, 2024

Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update

Read more
Aug 2, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Jul 29, 2024

Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024

Read more
Jul 5, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Jul 3, 2024

Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference

Read more
Jun 27, 2024

Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025

Read more
Jun 7, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Jun 5, 2024

Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Read more
May 30, 2024

Insmed to Host Commercial Webinar on June 4, 2024

Read more
May 30, 2024

Insmed Announces Pricing of $650 Million Public Offering of Common Stock

Read more
May 28, 2024

Insmed Announces Proposed $500 Million Public Offering of Common Stock

Read more
May 28, 2024

Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

Read more
May 27, 2024

Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

Read more
May 20, 2024

Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session

Read more
May 9, 2024

Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update

Read more
May 7, 2024

Insmed To Present at the BofA Securities Health Care Conference 2024

Read more
May 3, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Apr 25, 2024

Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024

Read more
Apr 5, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Mar 27, 2024

Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

Read more
Mar 5, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Feb 29, 2024

Insmed To Present at Three March Conferences

Read more
Feb 28, 2024

Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health

Read more
Feb 22, 2024

Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update

Read more
Feb 8, 2024

Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024

Read more
Feb 2, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Jan 5, 2024

Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference

Read more
Jan 4, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Jan 2, 2024

Insmed To Present at the 42nd Annual J.P. Morgan Healthcare Conference

Read more
Dec 5, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Nov 29, 2023

Insmed To Present at the Nasdaq 49th Investor Conference

Read more
Nov 8, 2023

Insmed To Present at Two November Conferences

Read more
Nov 3, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Nov 2, 2023

Insmed Holds Second Annual Global Day of Good to Benefit Communities Across the Globe

Read more

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Investor Presentation

View the latest Insmed Investor Presentation

Download

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Press Releases

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Footer